Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bosse

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2025
Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastomaJosephine G M Strijker, Guillem Pascual-Pasto, Grant P Grothusen, et al.
Medrxiv : the Preprint Server for Health Sciences|February 7, 2023
Germline pathogenic variants in 786 neuroblastoma patientsJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Nature Communications|August 14, 2025
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancersAlberto D Guerra, Smita Matkar, Christina Acholla, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaAmber K Weiner, Alexander B Radaoui, Matthew Tsang, et al.
Cancer Discovery|April 13, 2026
IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancersHai-Feng Zhang, Edouard De Dreuzy, Yue Zhou Huang, et al.
Cancer Cell|October 25, 2024
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaAmber K Hamilton, Alexander B Radaoui, Matthew Tsang, et al.
Cancer Cell|December 31, 2021
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicitySabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2025
Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastomaJosephine G M Strijker, Guillem Pascual-Pasto, Grant P Grothusen, et al.
Medrxiv : the Preprint Server for Health Sciences|February 7, 2023
Germline pathogenic variants in 786 neuroblastoma patientsJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Nature Communications|August 14, 2025
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancersAlberto D Guerra, Smita Matkar, Christina Acholla, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaAmber K Weiner, Alexander B Radaoui, Matthew Tsang, et al.
Cancer Discovery|April 13, 2026
IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancersHai-Feng Zhang, Edouard De Dreuzy, Yue Zhou Huang, et al.
Cancer Cell|October 25, 2024
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastomaAmber K Hamilton, Alexander B Radaoui, Matthew Tsang, et al.
Cancer Cell|December 31, 2021
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicitySabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, et al.
Pageof 6